The global Seasonal Affective Disorder (SAD) Therapeutics Market is projected to be valued at USD 962.4 million in 2025, reaching USD 1,523.4 million by 2035, with a compound annual growth rate (CAGR) of 4.7% during the forecast period. The market is driven by rising prevalence of SAD especially in fall/winter seasons-in tandem with growing mental …